Emcure Pharmaceuticals Ltd.

₹1,978.9

16.1 (0.8%)

EMCURE Share Price

Pharmaceuticals & Biotechnology

As on September 11, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 37,567 Cr

P/E Ratio40.59

Dividend Yield0.02 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,941.74	Bullish
10-DMA	1,905.06	Bullish
20-DMA	1,887.25	Bullish
50-DMA	1,892.41	Bullish
100-DMA	1,808.53	Bullish
200-DMA	1,646.71	Bullish

Historical Performance

1 Year

43.7%

3 Years

N/A

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	92,035	78,960	66,583	59,858	58,554
Total Expenditure	74,578	64,271	54,285	48,046	45,255
Other Income	1,315	728	570	459	635
Operating Profit	18,772	15,416	12,867	12,271	13,934
Interest	1,437	1,758	2,371	2,136	1,760
Depreciation	4,150	3,841	3,124	2,601	2,449
Profit Before Tax	12,871	9,713	7,272	7,472	9,725
Consolidated Net Profit	9,244	6,813	4,982	5,320	6,622
Adjusted EPS	49	36	28	29	37

Compounded Sales Growth

10 Years:16.1

5 Years:8.7

3 Years:9

TTM:3.1

Compounded Profit Growth

10 Years:10.6

5 Years:18.7

3 Years:11.7

TTM:6.3

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:46.7

Return on Equity

10 Years:13.3

5 Years:36.6

3 Years:27.5

last year:48.8

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	1,896	1,895	1,812	1,809	1,809
Total Reserves	47,484	42,448	27,566	23,054	17,908
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	5,842	8,119	13,771	9,046	8,684
Other Current Liabilities	10,937	5,473	8,548	7,122	6,490
Short Term Borrowings	7,955	4,746	9,472	11,320	10,846
Total Liabilities	94,731	81,217	77,094	65,734	59,474
Capital Work in Progress	1,721	1,241	1,323	4,035	3,098
Long Term Loans & Advances	2,358	1,607	1,436	1,143	1,117
Currents Investments	---	760	2,997	---	---
Short Term Loans and Advances	3,986	2,953	2,391	2,675	2,665
Total Current Assets	56,121	45,559	42,545	38,359	34,241
Total Assets	94,731	81,217	77,094	65,734	59,474
Adjusted Book Value	260	234	162	137	109

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 40.59, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 20.7%, indicating sustained price appreciation.
The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹18772 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹92035 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1462169.4

No. of Shares: 739 (Approx)

Performance:46.2%

462169.4

NIFTY Performance: -6.8%

1 day Top Gainers